Survivin-TCR

Survivin-TCR (Sur-TCR) is an engineered T-cell therapy that utilizes a T-cell receptor (TCR) specific for the intracellular protein survivin (BIRC5), presented by the HLA-A2 molecule. Survivin is an anti-apoptotic protein that is highly expressed in various malignancies, including acute myeloid leukemia (AML) and lymphoid leukemias, but is largely absent in healthy adult tissues. Developed by researchers at Baylor College of Medicine, this therapy aims to provide a targeted immune response against survivin-positive cancer cells. In recent preclinical studies, Survivin-TCR T cells have been co-engineered with a synapse-stabilizing receptor (SSR) targeting CD38 to enhance signaling and cytotoxic immune synapse formation, thereby improving efficacy against tumor cells with suboptimal antigen or HLA expression.

Other names

Survivin-specific T cell receptorSurvivin-specific TCR T cellsSur-TCR T cells